The Food and Drug Administration has given Bayer's experimental blood
cancer treatment copanlisib a priority review designation after the drug showed promise in fighting back
follicular lymphoma in 60 % of participants in a mid-stage clinical trial.
The combination of rituximab (Rituxan) and the novel immunotherapy pidilizumab (CT - 011) is both active and well tolerated in
follicular lymphoma patients, according to results of a phase II trial presented by Jason R. Westin, MD, of the MD Anderson
Cancer Center in Houston, at the American Society of Hematology (ASH) meeting in Atlanta.
According to the National
Cancer Institute at the National Institutes of Health, there is an estimated 60,220 new cases and 1,850 deaths from thyroid cancer in the United States alone.5 Thyroid cancer is classified into four different types: papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid c
Cancer Institute at the National Institutes of Health, there is an estimated 60,220 new cases and 1,850 deaths from thyroid
cancer in the United States alone.5 Thyroid cancer is classified into four different types: papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid c
cancer in the United States alone.5 Thyroid
cancer is classified into four different types: papillary thyroid cancer, follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid c
cancer is classified into four different types: papillary thyroid
cancer, follicular thyroid cancer, medullary thyroid cancer, and anaplastic thyroid c
cancer,
follicular thyroid
cancer, medullary thyroid cancer, and anaplastic thyroid c
cancer, medullary thyroid
cancer, and anaplastic thyroid c
cancer, and anaplastic thyroid
cancercancer.